<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114490">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143167</url>
  </required_header>
  <id_info>
    <org_study_id>RETRAP</org_study_id>
    <secondary_id>2011-002959-34</secondary_id>
    <nct_id>NCT02143167</nct_id>
  </id_info>
  <brief_title>Resistance Training and Amino Pyridine in Multiple Sclerosis</brief_title>
  <acronym>RETRAP</acronym>
  <official_title>RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen Idec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged-release fampridine (SR-fampridine) can improving walking capacity in approximately
      40% of MS patients suffering from this by overcoming partly or total conduction block due to
      demyelination.

      Resistance training has been shown to provide the same kind of benefits for patients by
      targeting the muscular component of the motor unit. Thus by combining the two it is likely
      to see an synergistic effect.

      This trial is designed as a double blind, randomized placebo controlled trial with
      subsequent cross-over.

      Participants in the two arms will go through the same progressive training program targets
      at the lower limbs. For 24 weeks one group receives SR-fampridine and the other receives
      placebo. in the the end there is another four weeks of training after cross-over has been
      performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Muscle power in the lower limbs</measure>
    <time_frame>Muscle power will be measured after 14 weeks of resistance training.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Muscle power in the lower limbs is measured by dynamometry pre and post resistance training</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>Accelerometry is measured after 14 weeks of resistance training</time_frame>
    <safety_issue>No</safety_issue>
    <description>Activity measured by accelerometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity</measure>
    <time_frame>Walking capacity is measured after 26 weeks of resistance training</time_frame>
    <safety_issue>No</safety_issue>
    <description>Walking capacity measured by the Six Spot Step Test (SSST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking speed</measure>
    <time_frame>Walking speed is measured after 26 weeks of resistance training</time_frame>
    <safety_issue>No</safety_issue>
    <description>Walking speed measured by the Timed 25 Foot Walk (T25FW) and the 6-Minute Walking Test (6MWT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity in the lower limbs</measure>
    <time_frame>Funcyional capacity in the lower limbs is measured after 26 weeks of resistance training</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional capacity measured by the Chair Stand Test (CST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self rated walking capacity</measure>
    <time_frame>Self rated walking capacity is measured after 26 weeks of resistance training</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self rated walking capacity measured by the 12-Item Multiple Sclerosis Walking Scale (MSWS12)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of SR-fampridine followed by four weeks of inactive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of inactive placebo followed by four weeks of SR-fampridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-fampridine</intervention_name>
    <description>One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.
The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.</description>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
    <other_name>Fampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>SR-fampridine/placebo</arm_group_label>
    <arm_group_label>Placebo/SR-fampridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive
             multiple sclerosis (SPMS) or primary progressive multiple sclerosis (PPMS) fulfilling
             the McDonald criteria

          -  Expandend Disability Status Scale (EDSS) 3-6.5

          -  Pyramidal Functional Score ≥ 2

          -  Participants must be able to transport self to gym and to the University of Southern
             Denmark

          -  Participants must be able to complete T25FW and SSST

          -  Fertile female participants are obliged to use hormonal contraceptive measures

        Exclusion Criteria:

          -  History of epileptic seizures

          -  MS relapse or change in disease modifying treatment (DMT) within 60 days

          -  Cancer within five years

          -  Blood pressure ≥ 160/100

          -  Severe arrhythmia or ischaemic heart disease or unexplained abnormal cardiac
             auscultation

          -  ≥ ALT 90 U/l, ≥ BSP 210 U/l, ≥ γ-GT 230 U/l

          -  GFR &lt; 80 ml/min.

          -  History of severe pulmonary disease or unexplained abnormal pulmonary auscultation

          -  Pregnancy

          -  Breastfeeding

          -  Allergy to substances contained in prolonged release Fampridine tablets

          -  Concomitant treatment with carvedilol, propranolol or metformin.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik B Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik B Jensen, MD</last_name>
    <phone>+4526351153</phone>
    <email>henrik.boye.jensen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Egon Stenager, MD</last_name>
    <email>egon.stenager3@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sydvestjysk Sygehus</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Egon Stenager, MD</last_name>
    </contact>
    <investigator>
      <last_name>Egon Stenager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik B Jensen, MD</last_name>
      <phone>+4526351153</phone>
      <email>henrik.boye.jensen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Henrik B Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sygehus Sønderjylland</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Egon Stenager, MD</last_name>
    </contact>
    <investigator>
      <last_name>Egon Stenager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebælt</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Egon Stenager, MD</last_name>
    </contact>
    <investigator>
      <last_name>Egon Stenager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, Overgaard K, Ingemann-Hansen T. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology. 2009 Nov 3;73(18):1478-84.</citation>
    <PMID>19884575</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502.</citation>
    <PMID>20976768</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8.</citation>
    <PMID>19249634</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Henrik Boye Jensen</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
